Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Geographic Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

The geographic atrophy market has been comprehensively analyzed in IMARC’s new report titled “Geographic Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033”. Geographic atrophy is an advanced form of dry age-related macular degeneration that affects the retina, a part of the eye that sends information to the brain to enable sight. In this stage, the damage is so severe that it causes blind spots in the patient’s central vision. A patient can have both wet and dry age-related macular degeneration simultaneously and develop geographic atrophy independently of having wet age-related macular degeneration. This disease leads to sharply demarcated atrophy of the outer retinal tissue, retinal pigment epithelium, and choriocapillaris. The common symptoms experienced by patients are central vision loss, difficulty in low-light conditions, and trouble seeing colors. Initially, the sign is identified while reading when one or several letters are missing from a word or when looking at faces, a small region of the face is not clearly visible. Over several years, geographic atrophy causes the central vision to diminish and the visual acuity comes down to 20/200. However, it does not usually affect peripheral vision. Geographic atrophy can be identified by an ophthalmologist using retinal imaging and a dilated examination. In a dilated exam, geographic atrophy appears as a patch of the retina without dark melanin pigment. Imaging techniques can also be used to detect geographic atrophy, including optical coherence tomography (OCT), retinal color photographs, autofluorescence imaging, etc.

The increasing prevalence of retinal disorders along with the expanding geriatric population is primarily driving the geographic atrophy market. Additionally, the rising incidences of obesity and cardiovascular diseases (CVDs) on account of changing dietary patterns, sedentary lifestyles, and unhealthy habits like smoking are further creating a positive outlook for the market. In line with this, the escalating usage of smartphones, laptops, televisions, etc., which is leading to prolonged and excessive screen time, is also propelling the market growth. Moreover, the introduction of retinal gene therapies, which involve injecting adeno-associated virus (AAV) into the body to prevent the development of abnormal blood vessels, is further acting as a significant growth-inducing factor. Besides this, the widespread adoption of autofluorescence imaging technology to visualize the retinal pigment epithelium (RPE) in order to assess the progression rate of the disease is also bolstering the global market. Additionally, several key players are making substantial investments in developing imaging technologies that will contribute to the understanding of the genesis and pathophysiological mechanisms of geographic atrophy. This, in turn, is positively influencing the market growth. Numerous other factors, such as extensive R&D activities for launching innovative and effective drugs and the increasing expenditure on healthcare to facilitate access to affordable treatment options, are expected to drive the geographic atrophy market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the geographic atrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for geographic atrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the geographic atrophy market in any manner.

Time Period of the Study

  • Base Year: 2022
  • Historical Period: 2017-2022
  • Market Forecast: 2023-2033
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the geographic atrophy market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the geographic atrophy market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

This report also provides a detailed analysis of the current geographic atrophy marketed drugs and late-stage pipeline drugs.
 

In-Market Drugs

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Drug uptake and market performance
     

Late-Stage Pipeline Drugs

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Regulatory status
     

Key Questions Answered in this Report

Market Insights

  • How has the geographic atrophy market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
  • What was the country-wise size of the geographic atrophy market across the seven major markets in 2022 and what will it look like in 2033?
  • What is the growth rate of the geographic atrophy market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the size of the geographic atrophy patient pool (2017-2022) across the seven major markets?
  • What would be the forecasted patient pool (2023-2033) across the seven major markets?
  • What are the key factors driving the epidemiological trend of geographic atrophy?
  • What will be the growth rate of patients across the seven major markets?
     

Geographic Atrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for geographic atrophy drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the geographic atrophy market?

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Geographic Atrophy - Introduction
4.1 Overview
4.2 Epidemiology (2017-2022) and Forecast (2023-2033)
4.3 Market Overview (2017-2022) and Forecast (2023-2033)
4.4 Competitive Intelligence

5 Geographic Atrophy - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Geographic Atrophy - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2022)
7.2.2 Epidemiology Forecast (2023-2033)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2017-2022)
7.3.2 Epidemiology Forecast (2023-2033)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2017-2022)
7.4.2 Epidemiology Forecast (2023-2033)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2017-2022)
7.5.2 Epidemiology Forecast (2023-2033)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2017-2022)
7.6.2 Epidemiology Forecast (2023-2033)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2017-2022)
7.7.2 Epidemiology Forecast (2023-2033)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2017-2022)
7.8.2 Epidemiology Forecast (2023-2033)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2017-2022)
7.9.2 Epidemiology Forecast (2023-2033)

8 Geographic Atrophy - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Geographic Atrophy - Unmet Needs

10 Geographic Atrophy - Key Endpoints of Treatment

11 Geographic Atrophy - Marketed Products
11.1 List of Geographic Atrophy Marketed Drugs Across the Top 7 Markets
11.1.1    Drug Name - Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.

 12 Geographic Atrophy - Pipeline Drugs
12.1 List of Geographic Atrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Avacincaptad Pegol - IVERIC bio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Metformin
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Retinol deuterated - Alkeus Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Iptacopan- Novartis Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

 Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report

13. Geographic Atrophy - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Geographic Atrophy - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1    Geographic Atrophy - Market Size
14.2.1.1 Market Size (2017-2022)
14.2.1.2 Market Forecast (2023-2033)
14.2.2    Geographic Atrophy - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2017-2022)
14.2.2.2 Market Forecast by Therapies (2022-2032
14.3 Market Scenario - United States
14.3.1    Geographic Atrophy - Market Size
14.3.1.1 Market Size (2017-2022)
14.3.1.2 Market Forecast (2023-2033)
14.3.2    Geographic Atrophy - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2017-2022)
14.3.2.2 Market Forecast by Therapies (2023-2033)
14.3.3    Geographic Atrophy - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Geographic Atrophy - Market Size
14.4.1.1 Market Size (2017-2022)
14.4.1.2 Market Forecast (2023-2033)
14.4.2    Geographic Atrophy - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2017-2022)
14.4.2.2 Market Forecast by Therapies (2023-2033)
14.4.3    Geographic Atrophy - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Geographic Atrophy - Market Size
14.5.1.1 Market Size (2017-2022)
14.5.1.2 Market Forecast (2023-2033)
14.5.2    Geographic Atrophy - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2017-2022)
14.5.2.2 Market Forecast by Therapies (2023-2033)
14.5.3    Geographic Atrophy - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Geographic Atrophy - Market Size
14.6.1.1 Market Size (2017-2022)
14.6.1.2 Market Forecast (2023-2033)
14.6.2    Geographic Atrophy - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2017-2022)
14.6.2.2 Market Forecast by Therapies (2023-2033)
14.6.3    Geographic Atrophy - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Geographic Atrophy - Market Size
14.7.1.1 Market Size (2017-2022)
14.7.1.2 Market Forecast (2023-2033)
14.7.2    Geographic Atrophy - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2017-2022)
14.7.2.2 Market Forecast by Therapies (2023-2033)
14.7.3    Geographic Atrophy - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Geographic Atrophy - Market Size
14.8.1.1 Market Size (2017-2022)
14.8.1.2 Market Forecast (2023-2033)
14.8.2    Geographic Atrophy - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2017-2022)
14.8.2.2 Market Forecast by Therapies (2023-2033)
14.8.3    Geographic Atrophy - Access and Reimbursement Overview
14.9   Market Scenario - Japan
14.9.1    Geographic Atrophy  - Market Size
14.9.1.1 Market Size (2017-2022)
14.9.1.2 Market Forecast (2023-2033)
14.9.2    Geographic Atrophy - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2017-2022)
14.9.2.2 Market Forecast by Therapies (2023-2033)
14.9.3    Geographic Atrophy - Access and Reimbursement Overview

15 Geographic Atrophy - Recent Events and Inputs From Key Opinion Leaders

16 Geographic Atrophy Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats     

17 Appendix


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 4499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4